EHA 2026 | Phase I study of etentamig in R/R AL amyloidosis: safety & efficacy data
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses updated Phase I data for etentamig, a novel BCMA×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. He highlights the therapy’s favorable safety profile, low rates of cytokine release syndrome (CRS) and infections, and encouraging efficacy. He also considers the potential role of T-cell redirecting therapies in transforming the treatment landscape for AL amyloidosis. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
